As with EBRT + topoisomerase inhibitor combinations, the benefits of TRT + topoisomerase inhibitor treatment appears to depend on the timing of topoisomerase inhibitor administration: McCluskey et al. reported greater tumor growth delay in SK-N-BE(2C) and UVW/NAT tumor–bearing mice when topotecan was administered simultaneously with 131I-metaiodobenzylguanidine than when administered 24 h beforehand or afterward (52,53). Here, BRD2 is linked to neoplasm.